Drug
SNG001
SNG001 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
3
75%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
recruiting125%
completed375%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_2
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
NCT06999603
completedphase_2
ACTIV-2: A Study for Outpatients With COVID-19
NCT04518410
completedphase_3
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
NCT04732949
completedphase_2
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
NCT04385095
Clinical Trials (4)
Showing 4 of 4 trials
NCT06999603Phase 2
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
NCT04518410Phase 2
ACTIV-2: A Study for Outpatients With COVID-19
NCT04732949Phase 3
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
NCT04385095Phase 2
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4